ClinicalTrials.gg
Enrolling by invitationNCT06639126InT-FGDUpdated Apr 11, 2025

Intervention Study Focused on the Intestinal Microbiome to Evaluate the Impact of a Wild Thyme Extract (Thymus Serpyllum) Extract With Anti-inflammatory and Metabolic Properties Against Functional Gastrointestinal Disorders.

An interventional study of Wild thyme extract and Placebo in Functional Gastrointestinal Disorders, sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental. Enrolling by invitation at 1 site in Spain. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Feb 2024, registered Sep 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Gastrointestinal Diseases with a site in Spain — 6 open to participants now, 10 under way, 3 of them phase 3. Gastrointestinal Diseases · Spain.

Planned enrollment
22nd of 27
75 · median 172
Started
2024
with 1 other
No phase
10 of 35
1 open now
Registered
33rd of 35
by date

Among the 35 studies in Gastrointestinal Diseases with a site in Spain, this one is the 22nd largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2024, is one of 10 with no phase, and was the 33rd registered.

Gastrointestinal Diseases

549 studies on the registry are indexed under Gastrointestinal Diseases; 102 are open to participants now.

Browse Gastrointestinal Diseases studies →

Open to participants now

6 of the 35 studies in Gastrointestinal Diseases with a site in Spain are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 66 Gastrointestinal Diseases studies recruiting now, 30 (45%) set no upper age limit and 23 (35%) stop at 75 or younger; 19 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Gastrointestinal Diseases with a site in Spain, or all of them as a file.
02

Study summary

Functional gastrointestinal disorders (FGD), now known as disorders of gut-brain interactions (DGBI), are characterized by gastrointestinal symptoms linked to motility issues, visceral sensitivity, intestinal permeability, immune activation, neuroendocrine function, CNS processing, and gut microbiota. These disorders include symptoms like abdominal pain, diarrhea, constipation, bloating, fullness, nausea, and vomiting, associated with conditions like IBS and functional dyspepsia. The complex pathophysiology of FGDs is not fully understood, affecting one-third of gastroenterology consultations. Diagnosis and treatment follow Rome Foundation criteria, focusing on symptom management rather than underlying mechanisms. Nearly half the population will meet FGD criteria at some point, with significant overlap in symptoms and conditions.

The gut microbiota's role is crucial, affecting homeostasis and linked to FGDs through dysbiosis. Treatments include antibiotics, dietary changes, and fecal transplants. Prebiotics, including medicinal plant extracts like wild thyme (Thymus serpyllum L.), show promise. Wild thyme has traditionally treated respiratory and gastrointestinal issues and contains phenolic compounds with potential spasmolytic and antioxidant effects.

Preclinical studies show wild thyme extract benefits in inflammation, IBS, and metabolic syndrome models. Recent human trials indicate improvements in gut regularity and microbiota. This study proposes wild thyme extract as a dietary supplement to benefit digestive health in FGDs, hypothesizing its immunomodulatory and prebiotic properties can reduce inflammation and restore microbiota balance. Specific objectives include analyzing microbiome impact, barrier function, inflammation, and identifying prognostic biomarkers to predict treatment response.

Read the detailed description

Functional gastrointestinal disorders (FGD), recently referred to as disorders of gut-brain interactions (DGBI), are characterized by the presence of gastrointestinal symptoms related to abnormalities in motility, visceral sensitivity, intestinal permeability, immune activation, neuroendocrine function, central nervous system processing, and gut microbiota. The spectrum of symptoms occurring in these FGDs includes abdominal pain, diarrhea, constipation, bloating, a sense of fullness, nausea, and vomiting, and are associated with conditions such as irritable bowel syndrome (IBS), functional dyspepsia, recurrent abdominal pain, or functional constipation/diarrhea, etc. Generally, these diseases are marked by a highly complex pathophysiology that is not fully understood, representing at least one-third of medical consultations related to Gastroenterology. Diagnosis and classification are performed using standardized criteria recommended by the Rome Foundation. Additionally, current treatment approaches target predominant gastrointestinal and psychological symptoms, rather than identifying and addressing specific underlying pathophysiological mechanisms. Nearly half of the general population will meet the criteria for these disorders at some point, and these conditions often overlap within the same individual. IBS is one of the most frequent FGDs, manifesting with recurrent abdominal pain and alterations in stool form and frequency, with a prevalence reaching approximately 4-11% of the population. Functional dyspepsia is characterized by the presence of one or more of the following symptoms: postprandial fullness, early satiety, epigastric pain, or burning, unexplained by routine clinical examination, with a prevalence of around 7%. Functional constipation is associated with difficult, infrequent, or incomplete defecation symptoms that do not meet IBS criteria, and may include abdominal pain with or without bloating, though these symptoms are not predominant, with a prevalence of around 12%. In the case of functional diarrhea, there is recurrent passage of loose, watery stools that do not meet the criteria for IBS, where abdominal pain with or without bloating may be present but is not predominant; the estimated prevalence can reach up to 5%. Another condition that may be included is functional abdominal bloating and distension, characterized by subjective symptoms of abdominal heaviness, pressure, or a feeling of trapped gas (bloating), and an objectively measurable increase in abdominal girth (distension), which do not meet criteria for another functional intestinal disorder (although mild abdominal pain or minor changes in bowel habits may coexist), with a prevalence of around 3%. Finally, up to 11% of FGD cases have been proposed to have intestinal symptoms that cannot be attributed to an organic cause and do not meet the diagnostic criteria for the aforementioned conditions: irritable bowel syndrome, functional constipation, functional diarrhea, with or without bloating. A global survey conducted by the Rome Foundation has established that women have a higher frequency of experiencing some type of FGD (49%) compared to men (37%). Besides gender, several factors seem to increase the risk of developing these digestive disorders: gastroenteritis, a history of trauma or abuse, stress, psychological disorders (anxiety, depression), somatic symptoms (fatigue, headaches, and back pain), obesity, and lack of sleep. Due to the great diversity of diseases that can be considered as FGDs, it is currently not possible to establish a common therapeutic strategy for all of them. In this regard, the general principles of treatment are based on understanding the complexity of the pathophysiology of the disease in question, aiming to improve the dysregulation of the gut-brain axis, which appears to occur frequently. Therefore, the type of symptoms, their location, and physiological determinants will influence the treatment. Some simple and cost-effective treatments, such as laxatives or antidiarrheals, may be sufficient for some patients, although the scientific evidence for these treatments is limited. In the case of functional constipation or IBS with constipation, meta-analysis studies have shown the efficacy of drugs such as linaclotide or lubiprostone (which act as secretagogues through intestinal ion channels), or prokinetics such as prucalopride or tegaserod (which act through serotonin receptors (5-HT)); for diarrhea in IBS, rifaximin (a low-absorption intestinal antibiotic) or alosetron or ondansetron (5-HT3 receptor antagonists) are beneficial. However, if there is severe abdominal pain, treatment may include an antidepressant. Despite the existence of these treatments, not all are effective in all patients, so a significant proportion do not achieve satisfactory therapeutic benefit. Additionally, these treatments are not exempt from the risk of adverse reactions, which may exacerbate the delicate situation presented by some patients. Therefore, the development of new therapeutic strategies for FGDs, combining efficacy and safety, is of great interest for managing these patients. The gut microbiota comprises the set of microorganisms that develop in the intestine, establishing a symbiotic relationship with the host and being involved in numerous functions. Moreover, the gut microbiota communicates with the brain through neural signaling channels (autonomic and enteric nervous systems), endocrine (hypothalamic-pituitary-adrenal axis and enteroendocrine cells), and immune pathways. In fact, several studies have pointed out that the gut-brain microbiota axis is crucial for maintaining homeostasis, and its alteration may be related to the appearance of neurological disorders, thus contributing to the development of other conditions with a significant psychological component, such as FGDs. In this sense, it is currently accepted that the gut microbiota plays an important role in FGDs; supporting this, it has been shown that patients with IBS have a different gastrointestinal microbiome compared to healthy subjects, leading to a situation called intestinal dysbiosis. Furthermore, it has even been proposed that a specific composition of the gut microbiota may influence disease severity. On the other hand, it has also been indicated that alterations in the production of metabolites derived from the metabolic activity of the gut microbiota will actively participate in the development of these diseases. These metabolites include short-chain fatty acids (SCFAs) (acetate, propionate, and butyrate), metabolites derived from amino acids, and bile acids. In line with the above, this dysbiosis situation that seems to characterize various FGDs has led to the development of different treatment approaches aimed at alleviating the symptoms of these diseases, such as IBS, through manipulation of the luminal gut microbiota. Initially, these treatments could include non-absorbable antibiotics (such as rifaximin or neomycin), as well as dietary treatments (low-fermentable oligosaccharide diets, prebiotics, probiotics) and fecal microbiota transplantation. Prebiotics are defined as substrates that will be selectively utilized by microorganisms present in the intestinal lumen, thereby conferring a health benefit to the host. Traditionally, the term prebiotic was restricted to certain dietary carbohydrates; however, it is now accepted that medicinal plant extracts, which can influence the composition of the gut microbiota, may also be considered prebiotics. In this regard, various human studies with medicinal plant extracts have reported their ability to improve symptoms in patients suffering from FGDs. However, most of these trials have used small sample sizes, are observational, and use preparations or formulations that are not commercially available, which constitutes a significant limitation in these studies. Wild thyme (Thymus serpyllum L.) is a perennial shrub native to northern and central Europe. Its aerial parts have been used in Traditional Medicine to treat conditions related to the respiratory and gastrointestinal systems. Regarding the latter, it has been used for the symptomatic treatment of digestive disorders such as epigastric bloating, slow digestion, gas, and flatulence. The presence of non-volatile phenolic compounds, including flavonoids, polyphenolic acids, and triterpenes in these extracts, could justify their spasmolytic effects, as well as the stimulation of gastric juice secretion that facilitates food digestion. Moreover, these active compounds may exert antioxidant properties, making these extracts a potential source of natural antioxidants for the development of nutritional supplements or functional foods in the food industry. Preclinical studies have demonstrated that wild thyme extract has beneficial effects in experimental models of intestinal inflammation and irritable bowel syndrome, as well as in an experimental model of diet-induced metabolic syndrome in mice. In all these cases, the extract improved the chronic inflammatory state associated with the studied experimental models, potentially improving intestinal barrier function and restoring the intestinal dysbiosis characteristic of these intestinal and metabolic diseases. Recently, the first human clinical trial on the impact of a Thymus serpyllum extract formulation has been published, showing benefits in intestinal regularity and gut microbiota. Considering all the above, it is logical to think that the consumption of T. serpylli extract could benefit human digestive health. Therefore, we propose to conduct an intervention study with wild thyme extract as a dietary supplement to corroborate its health benefits against gastrointestinal discomforts, such as FGDs. Consequently, the hypothesis of the present study is related to FGDs being associated with alterations in intestinal homeostasis, where the loss of intestinal barrier function along with a situation of intestinal dysbiosis seem to play a key role in their development. Therefore, the administration of medicinal plant extracts with immunomodulatory and prebiotic properties may exert beneficial effects in these patients, given the lack of an optimal therapeutic strategy that combines efficacy and safety so far. Thus, the hypotheses proposed in this study are: H1: Dietary supplementation with wild thyme extract, with proven immunomodulatory properties, may have beneficial effects on FGDs by reducing the inflammatory response generated in these conditions. H2: Consumption of wild thyme extract in patients with FGDs could positively impact the dysbiosis situation characterizing these disorders by restoring the composition and function of the microbiome. H3: Analysis of the patient's microbiome could act as a predictive biomarker of treatment response. To confirm these hypotheses, the general objective is to analyze the impact of dietary intervention with a well-characterized wild thyme (T. serpylli) extract on the clinical response and prognosis of patients diagnosed with an FGD. With this general objective, several specific objectives are proposed: i) to analyze the impact on the composition of the gut microbiome in patients with FGDs; ii) to determine prognostic biomarkers through the analysis of microbiome parameters to predict clinical response, objective response rate to treatment, and disease progression.

03

Conditions studied

  • Functional Gastrointestinal Disorders

Keywords

  • Intestinal microbiota
  • Functional dyspepsia
  • Thymus vulgaris
  • Functional gastrointestinal disorders
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Clinical diagnosis of functional gastrointestinal disorder.

Exclusion criteria

Exclusion Criteria:

  • Obesity.
  • Antibiotic treatment.
  • Pregnancy.
  • Clinical diagnoses of Inflammatory bowel disease.
  • Clinical diagnosis of Celiac disease
  • Clinical diagnosis of Hematological pathologies.
  • Clinical diagnosis of or immunodeficiency diseases.
  • Treatments with opioids, prokinetics, laxatives, antispasmodics, NSAIDs and proton pump inhibitors (PPIs).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
75 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo treated with 600 mg/capsule/day of microcrystalline cellulose

    Other: Placebo

  • Experimental
    Active

    Group with wild thyme extract

    Dietary Supplement: Wild thyme extract

Interventions

  • Dietary supplementWild thyme extract

    All patients will be randomized (1:1) to receive the active thyme extract (600 mg/capsule/day or 600 mg/capsule/day of microcrystalline cellulose) in the form of capsules, administered orally and daily for 2 months

    Also known as: 600 mg/capsule/day of microcrystalline cellulose, 600 mg/capsule/day of thyme extract

  • OtherPlacebo

    600 mg/day microcrystalline cellulose

06

What researchers measure

Primary outcomes

  1. Evaluation of the composition of the intestinal microbiome

    Metagenomic studies from feces samples at two different points (initial and final point). Shallow shotgun metagenomic will se used to evaluate the composition of the gut microbiota in these samples.

    Time frame: From enrollment to the end of treatment at 8 weeks

07

Study locations

1 site
  • Alba Rodriguez Nogales
    Granada, 18198, Spain
08

References and documents

Publications

  • Ruiz-Malagon AJ, Rodriguez-Sanchez MJ, Rodriguez-Sojo MJ, Vezza T, Pischel I, Algieri F, Rodriguez-Cabezas ME, Rodriguez-Nogales A, Galvez J. Intestinal anti-inflammatory and visceral analgesic effects of a Serpylli herba extract in an experimental model of irritable bowel syndrome in rats. Front Pharmacol. 2022 Sep 2;13:967644. doi: 10.3389/fphar.2022.967644. eCollection 2022. PubMed 36120292 ↗
  • Pavel M, Vostinaru O, Mogosan C, Ghibu S. Phytochemical and pharmacological research on some extracts obtained from Serpylli herba. Farmacia 2011;59:77-84.
  • Knaub, K., Schön, C., Suarez, C.G. and Pischel, I. (2022) Effects of a Food Supplement with a Wild Thyme (Thymus serpyllum L.) Extract on Gut Health and the Microbiome in Humans: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial. Food and Nutrition Sciences, 2022;13:931-949.
  • Ruiz-Malagon AJ, Rodriguez-Sojo MJ, Hidalgo-Garcia L, Molina-Tijeras JA, Garcia F, Pischel I, Romero M, Duarte J, Diez-Echave P, Rodriguez-Cabezas ME, Rodriguez-Nogales A, Galvez J. The Antioxidant Activity of Thymus serpyllum Extract Protects against the Inflammatory State and Modulates Gut Dysbiosis in Diet-Induced Obesity in Mice. Antioxidants (Basel). 2022 May 28;11(6):1073. doi: 10.3390/antiox11061073. PubMed 35739969 ↗
  • Jaric S, Mitrovic M, Pavlovic P. Review of Ethnobotanical, Phytochemical, and Pharmacological Study of Thymus serpyllum L. Evid Based Complement Alternat Med. 2015;2015:101978. doi: 10.1155/2015/101978. Epub 2015 Jul 22. PubMed 26265920 ↗
  • Algieri F, Rodriguez-Nogales A, Garrido-Mesa N, Zorrilla P, Burkard N, Pischel I, Sievers H, Benedek B, Feistel B, Walbroel B, Rodriguez-Cabezas ME, Galvez J. Intestinal anti-inflammatory activity of the Serpylli herba extract in experimental models of rodent colitis. J Crohns Colitis. 2014 Aug;8(8):775-88. doi: 10.1016/j.crohns.2013.12.012. Epub 2014 Jan 8. PubMed 24411672 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Dec 2024, 10 months.

Of 127 non-industry interventional studies with no phase under Gastrointestinal Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 46. This study's 10 months is below that.

Counting every sponsor, half of 149 studies reached it within 24 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2024
First posted
Oct 15, 2024
StartActual
Feb 1, 2024
Primary completionActual
Dec 1, 2024
CompletionEst.
Apr 30, 2025
Last update
Apr 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06639126
Lead sponsor
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Responsible party
Alba Rodriguez Nogales (Professor, Advanced Bionics) — Principal investigator
First posted
Oct 15, 2024
Start date
Feb 1, 2024
Primary completion
Dec 1, 2024
Completion
Apr 30, 2025 (estimated)
Last update
Apr 11, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion